Evolution and clinical implications of lymphopenia in patients with relapsing remitting multiple sclerosis on treatment with fingolimod

被引：0
|
作者：
Costa Arpin, E. [1 ]
Pato Pato, A. [2 ]
Rodriguez Regal, A. [3 ]
Ramos Rua, L. [4 ]
Lorenzo, J. R. [2 ]
Amigo Jorrin, M. D. C. [3 ]
Prieto Gonzalez, J. M. [1 ]
机构：
[1] Hosp Clin Univ, Neurol, Santiago De Compostela, Spain
[2] Hosp POVISA, Neurol, Vigo, Spain
[3] Complejo Hosp, Neurol, Pontevedra, Spain
[4] Hosp Comarcal, Neurol, Monforte De Lemos, Spain
来源：
MULTIPLE SCLEROSIS JOURNAL | 2016年 / 22卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
EP1542
引用
收藏
页码：805 / 806
页数：2
相关论文
共 50 条
  • [1] Characterization of lymphopenia in relapsing-remitting multiple sclerosis patients treated with dimethyl fumarate and fingolimod
    Nakhaei-Nejad, M.
    Barilla, D.
    Lee, C-H.
    Blevins, G.
    Giuliani, F.
    MULTIPLE SCLEROSIS JOURNAL, 2017, 23 : 618 - 618
  • [2] Fingolimod hydrochloride for the treatment of relapsing remitting multiple sclerosis
    Thomas, Katja
    Proschmann, Undine
    Ziemssen, Tjalf
    EXPERT OPINION ON PHARMACOTHERAPY, 2017, 18 (15) : 1649 - 1660
  • [3] Treatment of relapsing-remitting multiple sclerosis with fingolimod in routine clinical practice
    Alcala-Vicente, Carmen
    Perez-Miralles, Francisco C.
    Gascon-Gimenez, Francisco
    Bosca-Blasco, Isabel
    Navarre-Gimeno, Arantxa
    Coret-Ferrer, Francisco
    Casanova-Estruch, Bonaventura
    REVISTA DE NEUROLOGIA, 2017, 64 (10) : 445 - 453
  • [4] Transcriptional modulation induced by fingolimod treatment in Relapsing Remitting Multiple Sclerosis patients
    Clarelli, F.
    Provero, P.
    Ferre, L.
    Sferruzza, G.
    Mascia, E.
    Sorosina, M.
    Moiola, L.
    Martinelli, V.
    Comi, G.
    Boneschi, F. Martinelli
    Esposito, F.
    EUROPEAN JOURNAL OF HUMAN GENETICS, 2019, 27 : 551 - 552
  • [5] ORAL FINGOLIMOD FOR THE TREATMENT OF RELAPSING-REMITTING MULTIPLE SCLEROSIS
    Vosiliou, S.
    DRUGS OF TODAY, 2010, 46 (05) : 315 - 325
  • [6] Transcriptional modulation induced by fingolimod treatment in relapsing remitting multiple sclerosis patients
    Sferruzza, G.
    Clarelli, F.
    Provero, P.
    Ferre, L.
    Mascia, E.
    Moiola, L.
    Martinelli, V.
    Comi, G.
    Boneschi, F. Martinelli
    Esposito, F.
    MULTIPLE SCLEROSIS JOURNAL, 2018, 24 : 685 - 685
  • [7] Use of fingolimod in patients with relapsing remitting multiple sclerosis in Kuwait
    Alroughani, R.
    Ahmed, S. F.
    Behbehani, R.
    Al-Hashel, J.
    CLINICAL NEUROLOGY AND NEUROSURGERY, 2014, 119 : 17 - 20
  • [8] Fingolimod for relapsing-remitting multiple sclerosis
    La Mantia, Loredana
    Tramacere, Irene
    Firwana, Belal
    Pacchetti, Ilaria
    Palumbo, Roberto
    Filippini, Graziella
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2016, (04):
  • [9] Clinical efficacy, safety, and tolerability of fingolimod for the treatment of relapsing-remitting multiple sclerosis
    Gajofatto, Alberto
    Turatti, Marco
    Monaco, Salvatore
    Benedetti, Maria Donata
    DRUG HEALTHCARE AND PATIENT SAFETY, 2015, 7 : 157 - 167
  • [10] Effectiveness of fingolimod in Spanish patients with relapsing-remitting multiple sclerosis in the clinical practice
    Meca-Lallana, V.
    Martinez Yelamos, S.
    Mallada, J.
    Meca-Lallana, J.
    Martinez, M.
    Marzo, E.
    Duran, C.
    Ayuso, T.
    Barrero, F.
    Romero, R.
    Guillen, R.
    Ricart, J.
    Garcia, E.
    MULTIPLE SCLEROSIS JOURNAL, 2017, 23 : 855 - 855
12345